Top of the morning, and what a cold one it is. A bit of an arctic freeze has descended upon many of us on this side of the pond, but we are keeping warm thanks to — you guessed it — multiple cups of stimulation. This is why coffee kettles were invented, after all. So fire it up, pour a hot one, and please enjoy the tidbits below. Hope your day goes well and you remain toasty …

When two generic drug makers scrambled last July to recall hundreds of lots of the valsartan blood pressure drug, a third company unaffected by the recall saw a “one-off opportunity” to significantly increase prices, USA Today writes. Teva Pharmaceutical (TEVA) and Prinston Pharmaceutical recalled the meds after testing revealed small amounts of a probable carcinogen, but the same drugs produced by Alembic Pharmaceuticals did not show contamination. And Alembic more than tripled the price of 17 of its own formulations of valsartan, from 329 percent to 469 percent.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy